Hjem
per omviks bilde

per omvik

Emeritus
  • E-postper.omvik@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2012). Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: A LIFE study. American Journal of Hypertension. 1017-1023.
  • Vis forfatter(e) (2011). Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of Hypertension. 997-1004.
  • Vis forfatter(e) (2009). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study. American Heart Journal. 177-184.
  • Vis forfatter(e) (2009). Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure. 348-361.
  • Vis forfatter(e) (2009). Left ventricular long-axis function in treated haemochromatosis. The International Journal of Cardiac Imaging. 237-247.
  • Vis forfatter(e) (2009). Left ventricular diastolic function in patients with treated haemochromatosis. Scandinavian Cardiovascular Journal. 32-38.
  • Vis forfatter(e) (2009). Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 306-312.
  • Vis forfatter(e) (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
  • Vis forfatter(e) (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
  • Vis forfatter(e) (2008). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. American Heart Journal. 177-184.
  • Vis forfatter(e) (2008). Losartan compared with atenolol has positive effects on lipid metabolism in patients with hypertension and left ventricular hypertrophy: The LIFE Study. Journal of Hypertension.
  • Vis forfatter(e) (2007). Reduced exercise capacity in genetic haemochromatosis. European Journal of Cardiovascular Prevention & Rehabilitation. 470-475.
  • Vis forfatter(e) (2007). Left atrial size and risk of major cardiovascular events during antihypertensive treatment - Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 311-316.
  • Vis forfatter(e) (2006). Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure. 220-226.
  • Vis forfatter(e) (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. The Journal of Clinical Hypertension. 152-158.
  • Vis forfatter(e) (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Hypertension. 152-158.
  • Vis forfatter(e) (2005). The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Journal of the American College of Cardiology. 770-775.
  • Vis forfatter(e) (2005). Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 46-52.
  • Vis forfatter(e) (2005). Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 198-202.
  • Vis forfatter(e) (2005). Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 580-585.
  • Vis forfatter(e) (2005). Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 1924-1931.
  • Vis forfatter(e) (2004). The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International. 1014-1049.
  • Vis forfatter(e) (2004). Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study. Blood Pressure. 376-384.
  • Vis forfatter(e) (2004). Hypertensjon og hjertesykdom. Tidsskrift for Den norske legeforening. 802-805.
  • Vis forfatter(e) (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
  • Vis forfatter(e) (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
  • Vis forfatter(e) (2004). Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians. Blood Pressure Monitoring. 167-172.
  • Vis forfatter(e) (2004). Behandling av høyt blodtrykk hos pasienter med venstre<BR/>ventrikkel-hypertrofi. Tidsskrift for Den norske legeforening. 788-791.
  • Vis forfatter(e) (2004). Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 381-389.
  • Vis forfatter(e) (2003). The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). Blood Pressure. 211-219.
  • Vis forfatter(e) (2003). Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Annals of Internal Medicine. 169-177.
  • Vis forfatter(e) (2003). Allergi, astma og livsstil - epidemiologisk grunnlag - utbredelse. Fagbladet Allergi i praksis. 7-9.
  • Vis forfatter(e) (2003). Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine. 901-906.
  • Vis forfatter(e) (2002). Twenty-four-hour ambulatory blood pressure monitoring in atrial fibrillation. Blood Pressure Monitoring. 149-156.
  • Vis forfatter(e) (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 1879-1886.
  • Vis forfatter(e) (2002). Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Journal of Hypertension. 1223-1229.
  • Vis forfatter(e) (2002). Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Journal of the American Medical Association (JAMA). 1491-1498.
  • Vis forfatter(e) (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 995-1003.
  • Vis forfatter(e) (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 1004-1010.
  • Vis forfatter(e) (2001). Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • Vis forfatter(e) (2001). A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Managed Care Interface. 82-87.
  • Vis forfatter(e) (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
  • Vis forfatter(e) (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
  • Vis forfatter(e) (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
  • Vis forfatter(e) (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
  • Vis forfatter(e) (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
  • Vis forfatter(e) (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
  • Vis forfatter(e) (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • Vis forfatter(e) (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • Vis forfatter(e) (1999). Reproducibility of salt sensitivity testing using a dictary approach in essential hypertension. Journal of Human Hypertension. 375-384.
  • Vis forfatter(e) (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation. Scandinavian Cardiovascular Journal. 24.
  • Vis forfatter(e) (1998). Årsaker til og konsekvenser av mild hypertensjon? Tidsskrift for Den norske legeforening. 4396-4398.
  • Vis forfatter(e) (1998). The Bergen Blood pressure Study: changes in cardiac structure and function in offspring of hypertensive families. European Heart Journal. 474-474.
  • Vis forfatter(e) (1998). Konsensus om hypertensjon? Tidsskrift for Den norske legeforening. 3979-3981.
  • Vis forfatter(e) (1998). Is salt sensitivity a temporary phenomenon? Journal of Hypertension. 150-150.
  • Vis forfatter(e) (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for months months. American Journal of Hypertension. 1178-1187.
  • Vis forfatter(e) (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
  • Vis forfatter(e) (1998). Factors Influencing Left Ventricular Mass in Salt Sensitive and Salt Resistant Essential Hypertensive Patients. Blood Pressure. 223-230.
  • Vis forfatter(e) (1998). Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension. 989-997.
  • Vis forfatter(e) (1998). Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney International. 1455-1460.
  • Vis forfatter(e) (1997). Regression of left ventricular hypertrophy in type-1 diabetic patients using doxazosin as antihypertensive therapy @<abstract@>. Journal of Hypertension. 40.
  • Vis forfatter(e) (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Vis forfatter(e) (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Vis forfatter(e) (1997). Angiotensin converting enzyme inhibition and alpha<SUB>1</SUB>-receptor blockade as antihypertensive therapy in type-1 diabetic patients. American Journal of Hypertension. 121A.
  • Vis forfatter(e) (1996). Factors influencing left ventricular mass in hypertensive type-1 diabetic patients. American Journal of Hypertension. 65A.
Rapport
  • Vis forfatter(e) (2000). Hjerteinfarkt (revidert utgave). .
Vitenskapelig foredrag
  • Vis forfatter(e) (2003). Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).
  • Vis forfatter(e) (2002). The impact of concomitant diabtes on changes in left ventricular structure and function during antihypertensive treatment (the LIFE study).
  • Vis forfatter(e) (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Vis forfatter(e) (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Vis forfatter(e) (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Vis forfatter(e) (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Vis forfatter(e) (1999). Troponin I and T in atrial fibrillation.
  • Vis forfatter(e) (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation.
  • Vis forfatter(e) (1997). The alerting reaction to conventional blood pressure measurement is more pronounced in offspring of hypertensive than normotensive parents.
  • Vis forfatter(e) (1997). Increased alerting reaction to conventional blood pressure measurement in offspring of hypertensive parents.
Fagbok
  • Vis forfatter(e) (2000). Hjerteinfarkt (revidert utgave). Nasjonalforeningen. Det norske råd for hjerte og karsykdommer.
Kronikk
  • Vis forfatter(e) (2004). Hvorfor ikke alltid diuretika? Tidsskrift for Den norske legeforening. 1419-1420.
  • Vis forfatter(e) (1999). Helsefare på Haukeland sykehus. Bergens Tidende.
  • Vis forfatter(e) (1998). Will the millimetre of mercury be replaced by the kilopascal? Journal of Hypertension. 1055-1056.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2014). Hemodynamics and Hypertension. 14 sider.
  • Vis forfatter(e) (2000). Pågående multisenterstudier i hypertensjon - faglig medisinsk betydning og konsekvenser for pasienten. 4 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2005). Influence of hypertension on angiographic findings in patients with angina pectoris. American Journal of Hypertension. 175A.
  • Vis forfatter(e) (2004). Blood pressure and cardiovascular risk factors in hypertensive patients referred to a regional hospital in Ghana. American Journal of Hypertension. A196.
Poster
  • Vis forfatter(e) (2003). Comparison of blood pressure measurements by the Keito machine to casual blood pressure measured by physicians.
  • Vis forfatter(e) (1999). Factors influencing cardiac hypertrophy in type-1 diabetes mellitus.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2009). Central haemodynamics of hypertension. Archives of Medical Science. 220-228.

Se fullstendig oversikt over publikasjoner i CRIStin.